Streetbeat News

Regulatory

CLVR

CRON

OGI

VFF

British Columbia's legal cannabis market has seen a 40.9% increase in sales volume, but faces challenges such as an 11.7% decline in average prices and increased competition with 490 legal stores now operating. OrganiGram Holdings Inc (OGI), Rubicon, Village Farms International Inc (VFF), and Cronos Group Inc (CRON) are key players in the market. Australia's TGA has updated medicinal cannabis advertising guidelines, and Clever Leaves Holdings Inc. (CLVR) received Australian GMP certification for its Colombian facilities. Antigua and Barbuda's cannabis committee is reviewing legislation with a focus on youth impact.

Portfolio Pulse from Joana Scopel

January 10, 2024 | 10:03 pm

AAPL

The U.S. International Trade Commission (ITC) has opposed Apple Inc.'s motion to stay an import ban on some of its products pending an appeal. The ITC's decision could potentially lead to a ban on the import of certain Apple devices that infringe on a patent held by a competitor. Apple is likely to face challenges in its supply chain and sales if the ban is enforced.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 10:01 pm

SPY

In a recent speech, John Williams, President of the New York Federal Reserve, noted that financial markets are currently very sensitive to new data. This observation suggests that investors are closely monitoring economic indicators and adjusting their expectations accordingly. Williams did not comment on specific policy actions but emphasized the importance of data in shaping market reactions.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 9:52 pm

SPY

Federal Reserve Bank of New York President John Williams stated that recent volatility in the money markets has not impacted the federal funds rate. He also mentioned that the current demand for reserves is likely higher compared to the past, and emphasized the need for the Fed to consider its balance sheet strategy this year. Williams did not express concern over every fluctuation in the financial markets.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 9:51 pm

SPY

Federal Reserve Bank of New York President John Williams stated that the Fed is in a 'good place' with its current policy, which remains quite restrictive. He mentioned that the Fed has time to consider future actions regarding interest rates and emphasized the need to eventually return policy to more neutral levels. Williams also acknowledged the presence of some volatility in money market rates.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 9:51 pm

BTCUSD

SEC Chair Gary Gensler has warned investors about the risks associated with Bitcoin and crypto-related products. He emphasizes the need for caution due to the various uncertainties and potential for loss in the crypto market.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 9:47 pm

BTCUSD

SEC Chair Gary Gensler clarified that the SEC's approval for the listing and trading of certain spot Bitcoin ETP shares does not equate to an endorsement of Bitcoin itself.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 9:47 pm

BTCUSD

SEC Chair Gary Gensler stated that the SEC's actions on Wednesday should not be interpreted as a sign that the commission is ready to approve listing standards for securities tied to crypto assets.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 9:46 pm

BTCUSD

SEC Chair Gary Gensler has indicated that following a court's order, the most sustainable course of action is to approve the listing and trading of spot ETP (Exchange-Traded Product) shares, according to Reuters.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 9:46 pm

VTAK

Catheter Precision, Inc. (VTAK) released unaudited preliminary Q4 and FY23 results, reporting Q4 revenue of $129K and FY23 revenue of $442K. The company ended the year with $3.6 million in cash, total assets of $30.7 million, and shareholders' equity of $19.4 million. A significant net loss was reported for both Q4 and FY23, with a one-time $61 million write-off for goodwill impairment included in the annual loss. Key highlights include the launch of LockeT closure product in the US, expansion of sales and clinical personnel, and progress in clinical studies for LockeT. The company also received approval for its VIVO product in France and expanded its IP portfolio to 50 patents worldwide. CEO David Jenkins expressed optimism for 2024, citing momentum in product introductions and hospital evaluations. Final results are pending completion of year-end financial reporting and audit processes.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 9:45 pm